CD Capital led a $50m Series A-1 round in Neukio Biotherapeutics.

Synopsis

CD Capital led a $50m Series A-1 round in Neukio Biotherapeutics, a company committed to developing cell therapy products, with participation from Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital.

Principals

target

Neukio Biotheraupetics

bidder

Alwin Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (1)

carmel daniele

Founder and CEO at CD CAPITAL ASSET MANAGEMENT LTD

Investor

bidder

Deals

£ 178 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy